WEEXA BIOLOGICALS: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
WEEXA BIOLOGICALS
Largest movements
- Intangible fixed assets +€147,266
up €147,266 (+277%), from €53,083 to €200,350
- Cash +€21,236
up €21,236 (+22.1%), from €96,174 to €117,410
mainly Trade debts (+€125,345) and Debts after one year (+€75,000)
- Deferred charges and accrued income +€11,790
new in 2025: €11,790
- Receivables within one year +€6,989
up €6,989 (+25.0%), from €27,974 to €34,962
of which Trade receivables: +€8,736
- Stocks and contracts -€6,898
down €6,898 (-54.7%), from €12,611 to €5,712
- Trade debts +€125,345
up €125,345 (+345%), from €36,372 to €161,717
- Debts after one year +€75,000
new in 2025: €75,000
- Reserves -€34,504
down €34,504 (-50.3%), from €68,578 to €34,074
- Other debts +€14,322
up €14,322 (+147%), from €9,731 to €24,053
- Gross operating margin -€69,754
down €69,754, from €64,990 to -€4,764
- Depreciation +€29,265
up €29,265 (+555%), from €5,270 to €34,535
- Taxes -€7,745
down €7,745 (-65.3%), from €11,863 to €4,118
- Financial income +€7,522
up €7,522 (+386%), from €1,949 to €9,470
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €192,952 | €372,118 | +€179,166 | +92.9% |
| Fixed assets | 21/28 | €56,194 | €202,243 | +€146,049 | +260% |
| Intangible fixed assets | 21 | €53,083 | €200,350 | +€147,266 | +277% |
| Tangible fixed assets | 22/27 | €3,111 | €1,893 | -€1,218 | -39.1% |
| Furniture and vehicles | 24 | €3,111 | €1,893 | -€1,218 | -39.1% |
| Current assets | 29/58 | €136,758 | €169,875 | +€33,117 | +24.2% |
| Stocks and contracts in progress | 3 | €12,611 | €5,712 | -€6,898 | -54.7% |
| Stocks | 30/36 | €12,611 | €5,712 | -€6,898 | -54.7% |
| Amounts receivable within one year | 40/41 | €27,974 | €34,962 | +€6,989 | +25.0% |
| Trade receivables | 40 | €19,140 | €27,876 | +€8,736 | +45.6% |
| Other amounts receivable | 41 | €8,834 | €7,086 | -€1,747 | -19.8% |
| Cash at bank and in hand | 54/58 | €96,174 | €117,410 | +€21,236 | +22.1% |
| Deferred charges and accrued income | 490/1 | - | €11,790 | +€11,790 | |
| Total equity and liabilities | 10/49 | €192,952 | €372,118 | +€179,166 | +92.9% |
| Equity | 10/15 | €120,661 | €88,294 | -€32,367 | -26.8% |
| Contributions | 10/11 | €10,000 | €10,000 | = | 0.0% |
| Reserves | 13 | €68,578 | €34,074 | -€34,504 | -50.3% |
| Distributable reserves | 133 | €68,578 | €34,074 | -€34,504 | -50.3% |
| Investment grants | 15 | €42,083 | €44,220 | +€2,137 | +5.1% |
| Amounts payable | 17/49 | €72,291 | €283,824 | +€211,533 | +293% |
| Amounts payable after more than one year | 17 | - | €75,000 | +€75,000 | |
| Financial debts | 170/4 | - | €75,000 | +€75,000 | |
| Amounts payable within one year | 42/48 | €48,125 | €185,770 | +€137,645 | +286% |
| Financial debts | 43 | €159 | €0 | -€159 | -100% |
| Credit institutions | 430/8 | €159 | €0 | -€159 | -100% |
| Trade debts | 44 | €36,372 | €161,717 | +€125,345 | +345% |
| Suppliers | 440/4 | €36,372 | €161,717 | +€125,345 | +345% |
| Taxes, remuneration and social security | 45 | €1,863 | €0 | -€1,863 | -100% |
| Taxes | 450/3 | €1,863 | €0 | -€1,863 | -100% |
| Other amounts payable | 47/48 | €9,731 | €24,053 | +€14,322 | +147% |
| Accrued charges and deferred income | 492/3 | €24,166 | €23,054 | -€1,112 | -4.6% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €5,270 | €34,535 | +€29,265 | +555% |
| Other operating charges | 640/8 | €387 | €400 | +€12 | +3.2% |
| Gross operating margin | 9900 | €64,990 | -€4,764 | -€69,754 | |
| Operating profit (loss) | 9901 | €59,333 | -€39,699 | -€99,031 | |
| Financial income | 75/76B | €1,949 | €9,470 | +€7,522 | +386% |
| Recurring financial income | 75 | €1,949 | €9,470 | +€7,522 | +386% |
| Financial charges | 65/66B | €309 | €158 | -€151 | -49.0% |
| Recurring financial charges | 65 | €309 | €158 | -€151 | -49.0% |
| Profit (loss) for the period before taxes | 9903 | €60,972 | -€30,386 | -€91,358 | |
| Income taxes | 67/77 | €11,863 | €4,118 | -€7,745 | -65.3% |
| Profit (loss) for the period | 9904 | €49,110 | -€34,504 | -€83,613 | |
| Profit (loss) for the period to be appropriated | 9905 | €49,110 | -€34,504 | -€83,613 |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 22 October 2026 via checked.be.